While in T cell acute lymphoblastic leukemia, treatment modifies cellular metabolism from glutaminolysis to glycolysis to evade drug-induced cellular stress. One glycolytic enzyme important in cancer is pyruvate kinase M2 (PKM2) that provides a survival advantage to diseased cells and plays a role in...
Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012; 119: 1981-1987....
Treatment protocols for chronic myelogenous leukemia (CML) are provided below for chronic phase, accelerated phase, and blast phase. General treatment recommendations for chronic myelogenous leukemia Tyrosine kinase inhibitors (TKIs) are the drugs of choice for initial therapy of CML. [1] Imatinib was...
The goals of treatment of chronic myelogenous leukemia (CML) are threefold and have changed markedly since the advent of tyrosine kinase inhibitor (TKI) therapy. They are as follows: Hematologic remission (normal complete blood cell count [CBC] and physical examination (ie, no organomegaly) Cytoge...
Bosutinib is a second-generation tyrosine kinase inhibitor (TKI) approved for use in patients with newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase (CP) chronic myeloid leukemia (CML), as well as Ph-positive CP, accelerated phase, or blast phase (with chemotherapy) CML ...
Figure. Survival of BC patients after treatment with imatinib; data of the German CML Study IV Disclosures: German CML Study Group: Deutsche Krebshilfe: Research Funding; Novartis: Research Funding; German CompetenceNet : Research Funding; European LeukemiaNet: Research Funding; Roche: Research Fundin...
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014–1018. 94 Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D et al. High-...
The progression rate was significantly lower in patients treated with IM than in those treated without IM (0 vs. 28.6%, p=0.006). In summary, the survival outcomes of pediatric patients with CML were dramatically improved by treatment with IM compared to HSCT. 展开 ...
Engelman A, Rosenberg N (1990) Temperature-sensitive mutants of Abelson murine leukemia virus deficient in protein tyrosine kinase activity. J Virol 64(9):4242–4251 CAS Goldman JM, Melo JV (2003) Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med 349...
Fred Hutch and City of Hope "Face Off" regarding presentations focusing on multiple myeloma and chronic myeloid leukemia. During a recent Face-Off event, experts in the field of chronic myeloid leukemia (CML) and multiple mye...